首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1319156

全球肝癌診斷市場 - 2023-2030 年

Global Liver Cancer Diagnostics Market - 2023-2030

出版日期: 2023年07月31日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

全球肝癌診斷市場規模在2022 年達到86 億美元，預計到2030 年將達到141 億美元，2023-2030 年的年複合成長率為6.6%。肝癌是一種始於肝臟並可擴散至身體其他部位的惡性腫瘤。它是全球最常見的癌症類型之一。早期診斷是有效治療肝癌的關鍵。

目前，有幾種診斷肝癌的方法。這些方法包括電腦斷層掃描（CT）和磁共振成像（MRI）等成像檢查，以及測量某些蛋白質和激素水準的血液檢查。還可以進行活組織切片檢查，收集細胞用於化驗。如果醫生了解各種可用的診斷程序，就能有效地檢測肝癌並製定有效的治療策略。早期診斷對於改善患者預後至關重要。

此外，肝癌發病率的上升、新型肝癌檢測試驗獲批數量的增加以及用於肝癌診斷的成像系統的進步等因素有望在預測期內推動市場的發展。

市場動態

肝細胞癌早期檢測技術的進步有望推動全球肝癌診斷市場成長

2022 年8 月4 日，根據加州大學洛杉磯分校瓊森綜合癌症中心研究人員領導、50 多名研究人員參與的新研究，正在開發的新技術可能會帶來一種更好的方法來檢測早期肝細胞癌（HCC），HCC 佔原發性肝癌的80% 至85%，通常發生在肝硬化或慢性乙型肝炎病毒攜帶者身上。這種實驗方法分析的奈米顆粒被稱為細胞外囊泡或EVs，它們由正常細胞釋放，尤其是由腫瘤細胞和腫瘤微環境中的細胞釋放。

此外，加州大學洛杉磯分校的研究人員及其合作夥伴還開發了一種簡化的表面蛋白測定法（HCC EV SPA），能夠剖析和測量八個HCC EV亞群。科學家們相信，有朝一日，HCC EV SPA 技術將能快速、高靈敏、低成本地識別肝硬化高危患者的早期HCC。該技術由兩項強大的平台技術組成：從少量血漿樣本中純化HCC EV 的專有Click Beads 技術和測量HCC EV 亞群的多重即時免疫PCR 技術。

此外，研究人員還根據國際肝癌協會生物標記物開發指南，開展了一項用於檢測早期HCC 的2 期生物標記物研究。因此，早期檢測可以讓醫生和患者更早地開始治療，他們認為這將對生存率產生重大影響。因此，由於上述因素，市場有望在預測期內得到推動。

肝癌發病率的上升有望推動全球肝癌診斷市場的成長

據美國國家癌症研究所的監測、流行病學和最終結果（SEER）計劃估計，2023 年美國將診斷出41210 例新的肝癌和肝內膽管癌病例，預計約有29380 人死於原發性成人肝癌。五年相對生存率僅為21.6%。

患有乙型肝炎、丙型肝炎或肝硬化是成人原發性肝癌的重要風險因素。肝癌在男性中的發病率高於女性，在亞洲/太平洋島民和美洲印第安人/阿拉斯加原住民中也更為常見。因此，肝癌發病率的上升提高了早期檢測的必要性。因此，由於上述因素，市場有望在預測期內得到推動。

獲取肝癌診斷組織樣本的挑戰預計將阻礙全球肝癌診斷市場的成長

小腫瘤可能更難活體組織切片，因為它們可能無法在成像檢查中立即看到，或在體檢中觸及。腫瘤越小，活體組織切片就越精確，以便獲得足夠的組織樣本用於診斷。

肝臟活體組織切片手術可能會出現併發症，但如果由技術嫻熟的醫生進行，通常被認為是安全的。不過，由於肝臟血液供應豐富，活體組織切片過程中或之後有出血的危險。其他潛在風險包括感染、傷害鄰近器官和膽汁滲漏。考慮到出現這些問題的可能性，有必要仔細考慮在每種情況下進行活組織檢查的危險與好處。

因此，由於上述因素，預計在預測期內市場將受到阻礙。

俄烏衝突分析

俄羅斯和烏克蘭之間的持續衝突是一個具有深遠影響的地緣政治問題。在受衝突影響的地區，醫院、診斷實驗室和醫療設施等醫療基礎設施可能會遭到破壞或無法使用。這種破壞可能會影響肝癌診斷服務（如成像技術、活體組織切片程序和實驗室測試）的可用性和可及性。

衝突可能會中斷供應鏈，減少診斷設備、成像劑、活體組織切片工具和實驗室試劑等醫療用品的供應。這種匱乏可能導致肝癌診斷技術的延誤或限制，影響及時準確的診斷。

此外，戰爭還可能導致醫療專家（如放射科醫生、病理科醫生和腫瘤專科醫生）以及其他醫務人員流離失所。這種專業人才的流失可能會對受影響地區的肝癌診斷能力造成進一步的壓力，從而可能導致檢測和治療的延誤。

因此，考慮到上述因素，可以說戰爭對肝癌診斷市場造成了中度影響。

COVID-19 影響分析：

COVID-19 大流行對肝癌診斷產生了影響。 COVID-19 會加重現有的慢性肝病，並使肝癌的治療複雜化。從診斷到治療策略，大流行對肝癌患者的管理產生了重大影響。由於COVID-19 而修改篩查計劃，導致肝癌診斷延誤。在一項研究中，80.9% 的參與中心報告稱，大流行導致肝癌診斷延遲。

與此相反，在COVID-19 大流行期間，肝癌篩查的替代方法得到了實施，以適應醫療保健系統帶來的挑戰，並將接觸病毒的風險降至最低。大流行期間，遠程醫療被廣泛用於提供遠程醫療服務。通過虛擬會診，醫療服務提供者可以評估患者的症狀、回顧病史並提供肝癌篩查指導。

此外，風險評估工具可以幫助確定哪些人患肝癌的風險較高。這些工具會考慮年齡、性別、潛在肝病和其他風險因素。醫療保健提供者可以使用這些工具來確定是否需要進一步篩查或監測。

甲胎蛋白（AFP）腫瘤標誌物檢驗
實驗室檢驗
- 生物標記
  - 腫瘤胎兒和糖蛋白抗原
  - 酶和同工酶
  - 生長因子和受體
  - 分子標記物
  - 病理生物標記物
- 血液檢驗
  - 肝功能檢驗（LFT）
  - 凝血檢驗
  - 腎功能檢驗
  - 全血細胞計數（CBC）
  - 血液化學檢驗和其他檢驗
活組織檢查
- 細針穿刺活體組織切片
- 核心針活體組織切片
- 腹腔鏡檢查
影像學檢查
- 超音波
- 電腦斷層掃描(CT)
- 磁共振成像（MRI）
- 血管造影術
- 其他
其他

第9 章：按最終用戶分類

醫院
癌症研究所
診斷實驗室
其他

第10 章：按地區

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
南美洲
- 巴西
- 阿根廷
- 南美洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 澳大利亞
- 亞太其他地區
中東和非洲

第11 章：競爭格局

競爭格局
產品基準
公司佔有率分析
主要發展和戰略

第12 章：公司簡介

Abbott Laboratories
- 公司概況
- 產品組合和說明
- 財務概況
- 主要發展
F. Hoffmann-La Roche Ltd.
Qiagen NV
Thermo Fisher Scientific, Inc.
Siemens Healthineers
BD
Illumina, Inc.
Koninklijke Philips NV
Epigenomics AG
Fujifilm Medical Systems USA, Inc.
Sysmex Corporation

第13 章：附錄

簡介目錄

Product Code: MD6609

Market Overview

Global Liver Cancer Diagnostics Market reached US$ 8.6 billion in 2022 and is expected to reach US$ 14.1 billion by 2030 growing with a CAGR of 6.6% during the forecast period 2023-2030. Liver cancer is a malignant growth that starts in the liver and can spread to other parts of the body. It is one of the most common types of cancer worldwide. Early diagnosis is key to effectively treating liver cancer.

Currently, there are several diagnostic methods used to diagnose liver cancer. These include imaging tests, such as computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as blood tests that measure levels of certain proteins and hormones. Biopsies can also be performed to collect cells for lab tests. Doctors can effectively detect liver cancer and establish an efficient treatment strategy if they understand the various diagnostic procedures available. Early diagnosis is critical for improving patient outcomes.

Furthermore, the increasing prevalence of liver cancer, rising approvals for novel liver cancer detection tests, and advancement in the imaging systems for liver cancer diagnosis are the factors expected to drive the market over the forecast period.

Market Dynamics

Technological Advancement in the Earlier Detection of Hepatocellular Carcinoma is Expected to Drive the Global Liver Cancer Diagnostics Market Growth

On August 4, 2022, According to new research led by UCLA Jonsson Comprehensive Cancer Centre investigators and involving more than 50 researchers, new technology in development may lead to a better way to detect early-stage hepatocellular carcinoma (HCC), which accounts for 80% to 85% of primary liver cancers and typically occurs in patients with liver cirrhosis or chronic hepatitis B virus. The experimental method analyses and analyses nanoparticles known as extracellular vesicles, or EVs, which are released by normal cells but especially by tumor cells and cells within a tumor microenvironment.

Additionally, UCLA researchers and partners developed a simplified surface protein assay (HCC EV SPA) capable of dissecting and measuring eight HCC EV subpopulations. The scientists believe that the HCC EV SPA technology will one day allow for the quick, highly sensitive, and low-cost identification of early-stage HCC in at-risk patients with liver cirrhosis. It is made up of two powerful platform technologies: proprietary Click Beads for purifying HCC EVs from small volumes of plasma samples, and multiplex, real-time immune-PCR for measurement of HCC EV subpopulations.

Also, the researchers have conducted a Phase 2 biomarker study, following the International Liver Cancer Association biomarker development guideline for detecting early-stage HCC. Therefore, early detection allows physicians and patients to begin therapy sooner, which they believe will have a major influence on survival rates. Thus, owing to the above factors, the market is expected to drive over the forecast period.

The Increasing Prevalence of Liver Cancer is Expected to Drive the Global Liver Cancer Diagnostics Market Growth

According to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER), Program estimates that 41,210 new cases of liver and intrahepatic bile duct cancer will be diagnosed in the United States in 2023, with some 29,380 people expected to die of primary adult liver cancer. The five-year relative survival rate is just 21.6 percent.

Having hepatitis B, hepatitis C, or cirrhosis are significant risk factors for adult primary liver cancer. Liver cancer is more common in men than women and among Asian/Pacific Islander and American Indian/Alaska Native populations. Therefore, the rising occurrence of liver cancer raises the need for early detection. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Challenges for Obtaining a Tissue Sample for Liver Cancer Diagnosis is Expected to Hamper the Global Liver Cancer Diagnostics Market Growth

Small tumors can be more difficult to biopsy since they may not be immediately visible on imaging investigations or palpable during a physical examination. The smaller the tumor, the more exact the biopsy must be to acquire a sufficient tissue sample for diagnosis.

Complications are possible with liver biopsy procedures, however, they are typically regarded as safe when performed by skilled physicians. However, due to the liver's abundant blood supply, there is a danger of bleeding during or after the biopsy. Other potential risks include infection, harm to neighboring organs, and bile leakage. The likelihood of problems necessitates careful consideration of the dangers vs the advantages of performing a biopsy in each situation.

Thus, owing to the above factors, the market is expected to hamper over the forecast period.

Russia-Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine is a geopolitical issue with profound ramifications. Healthcare infrastructure, such as hospitals, diagnostic laboratories, and medical facilities, may suffer damage or be rendered inaccessible in conflict-affected areas. This disruption may affect the availability and accessibility of liver cancer diagnostic services such as imaging technologies, biopsy procedures, and laboratory tests.

Conflicts may interrupt supply chains and reduce the availability of medical supplies such as diagnostic equipment, imaging agents, biopsy tools, and laboratory reagents. This scarcity can cause delays or limits in liver cancer diagnostic techniques, affecting timely and accurate diagnosis.

In addition, the war may cause the displacement of healthcare experts such as radiologists, pathologists, and specialized oncologists, as well as other medical personnel. This loss of expertise may place a further strain on the afflicted regions' liver cancer diagnostic capabilities, perhaps leading to delays in detection and treatment.

Therefore, taking into account the factors mentioned above, it can be stated that the liver cancer diagnostic market experienced a moderate impact as a result of the war.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had an impact on liver cancer diagnosis. COVID-19 can exacerbate existing chronic liver disease and complicate the management of liver cancer. The pandemic has significantly impacted the management of liver cancer patients, from diagnosis to treatment strategies. The modification of screening programs due to COVID-19 has caused delays in liver cancer diagnosis. In a study, 80.9% of participating centers reported a delay in liver cancer diagnosis due to the pandemic.

In contrast, during the COVID-19 pandemic, alternative methods for liver cancer screening have been implemented to adapt to the challenges posed by the healthcare system and to minimize the risk of exposure to the virus. Telemedicine has been widely used during the pandemic to provide remote healthcare services. Virtual consultations allow healthcare providers to assess patients' symptoms, review medical history, and provide guidance on liver cancer screening.

Additionally, risk assessment tools can help identify individuals who are at a higher risk of developing liver cancer. These tools take into account factors such as age, gender, underlying liver disease, and other risk factors. Healthcare providers can use these tools to determine the need for further screening or surveillance.

Segment Analysis

The global liver cancer diagnostics market is segmented based on test type, end user, and region.

Hospitals from the End User Segment Account for 35.52% of the Market Share Owing to the Advanced Imaging Technologies, Integration of Test Results, Increased Diagnostic Testing Demand, and Increasing Number of Hospitals with Imaging Modalities and Screening Facilities.

Hospitals play a vital role in cancer diagnosis, with numerous advantages leading to precise diagnosis and appropriate disease management.

The hospital is equipped with cutting-edge imaging equipment such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scanners.

These cutting-edge diagnostic tests provide detailed, fascinating images of the liver to aid in the diagnosis, characterization, and staging of liver tumors. Specialized tests, such as CT angiography or diffusion-weighted imaging, may be performed in clinical laboratories to examine vascular involvement or detect subtle changes in the tumor.

For instance, Cancer Treatment Centers of America (CTCA) is now the City of Hope, joining forces to expand patient access to personalized, comprehensive cancer care. Moreover, the City of Hope is committed to providing the highest level of care for patients experiencing liver cancer and other gastrointestinal malignancies.

Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 39.6% of the Market Share Owing to the Rising Implementation of Novel Diagnostics, the Presence of Supportive Government Organizations, and Collaborations among Market Players

According to National Center for Biotechnology Information Article 2022, Texas has the highest age-adjusted incidence rate of hepatocellular carcinoma (HCC) in the United States. To address cancer prevention and early detection through research, the Cancer Prevention and Research Institute of Texas (CPRIT) has funded the Texas Collaborative Center for Hepatocellular Cancer (TeCH) to facilitate liver cancer research, education, and advocacy activities. TeCH and its committees facilitate connections and collaborations among HCC researchers and clinicians, healthcare leaders, biotechnology companies, and the public to reduce liver cancer mortality in Texas by 2030.

Additionally, on December 8, 2022, the Department of Veterans Affairs (VA) will research to discover the most efficient screening technique for liver cancer, a lethal malignancy that can be cured if detected early. This is the largest clinical experiment in the history of liver cancer screening. The trial will look into whether finding liver cancer early using a shortened MRI reduces patients' chance of death.

PREMIUM - PREventing Liver Cancer Mortality via Imaging with Ultrasound vs. MRI - the trial's goal is to evaluate whether screening using shortened MRI is better than ultrasound, the current standard of care, in lowering liver cancer fatalities in veterans. VA's Veterans Health Administration is the largest healthcare provider in the U.S. for patients with cirrhosis, a leading risk factor for liver cancer.

Enrollment will begin in 2023 and follow participants over eight years. This is the first clinical trial to compare the two screening methods for their effect on patient outcomes. Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V., Thermo Fisher Scientific, Inc., Siemens Healthineers, BD, Illumina, Inc., Koninklijke Philips N.V, Epigenomics AG, Fujifilm Medical Systems U.S.A., Inc., and Sysmex Corporation among others.

Why Purchase the Report?

To visualize the global liver cancer diagnostics market segmentation based on the test type, end user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of liver cancer diagnostics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global liver cancer diagnostics market report would provide approximately 53 tables, 50 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Test Type
3.2. Snippet by End User
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Clinical Trials by the Market Players for the Early Detection of Liver Cancer
  - 4.1.1.2. Development of New Biomarkers for the Early Detection of Liver Cancer
- 4.1.2. Restraints
  - 4.1.2.1. The High Cost of Liver Cancer Screening
- 4.1.3. Opportunity
  - 4.1.3.1. Rising Demand for Point-Of-Care Testing (POCT) in Liver Cancer Diagnostics
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Test Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 8.1.2. Market Attractiveness Index, By Test Type
8.2. Alpha-fetoprotein (AFP) tumor marker test*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Laboratory Tests
- 8.3.1. Biomarker
  - 8.3.1.1. Oncofetal and Glycoprotein Antigens
  - 8.3.1.2. Enzymes and Isoenzymes
  - 8.3.1.3. Growth Factors and Receptors
  - 8.3.1.4. Molecular Markers
  - 8.3.1.5. Pathological Biomarkers
- 8.3.2. Blood Tests
  - 8.3.2.1. Liver function tests (LFTs)
  - 8.3.2.2. Blood clotting tests
  - 8.3.2.3. Kidney function tests
  - 8.3.2.4. Complete blood count (CBC)
  - 8.3.2.5. Blood chemistry tests and other tests
8.4. Biopsy
- 8.4.1. Fine-needle aspiration biopsy
- 8.4.2. Core needle biopsy
- 8.4.3. Laparoscopy
8.5. Imaging
- 8.5.1. Ultrasound
- 8.5.2. Computed tomography (CT)
- 8.5.3. Magnetic resonance imaging (MRI)
- 8.5.4. Angiography
- 8.5.5. Others
8.6. Others

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Research Institutes
9.4. Diagnostic Laboratories
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.2.5.1. U.S.
  - 10.2.5.2. Canada
  - 10.2.5.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.3.5.1. Germany
  - 10.3.5.2. U.K.
  - 10.3.5.3. France
  - 10.3.5.4. Italy
  - 10.3.5.5. Spain
  - 10.3.5.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.5.1. Brazil
  - 10.4.5.2. Argentina
  - 10.4.5.3. Rest of South America
10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.5.5.1. China
  - 10.5.5.2. India
  - 10.5.5.3. Japan
  - 10.5.5.4. Australia
  - 10.5.5.5. Rest of Asia Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Product Benchmarking
11.3. Company Share Analysis
11.4. Key Developments and Strategies

12. Company Profiles

12.1. Abbott Laboratories*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. F. Hoffmann-La Roche Ltd.
12.3. Qiagen N.V.
12.4. Thermo Fisher Scientific, Inc.
12.5. Siemens Healthineers
12.6. BD
12.7. Illumina, Inc.
12.8. Koninklijke Philips N.V
12.9. Epigenomics AG
12.10. Fujifilm Medical Systems U.S.A., Inc.
12.11. Sysmex Corporation